Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00860379 · ClinicalTrials.gov registry record · Phase 4
The Effect of Selenium Supplementation Among Pediatric Patients With Burns
A Phase 4 study, sponsored by Shriners Hospitals for Children.
- Terminated
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
NCT00860379: Clinical Trial Phase 4 study, sponsored by Shriners Hospitals for Children.
NCT00860379 is a Phase 4 study that was terminated before completion, run by Shriners Hospitals for Children. The registered enrollment target is 14 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00860379, a Phase 4 study, was terminated before completion, sponsored by Shriners Hospitals for Children.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
Study Summary
The selenium status of children with major burns is suboptimal which may increase the incidence of infection. Se requirements during critical illness are not known. Results from this investigation may provide a tool for recommending Se supplements during burn injury. The hypothesis of this research is that Se supplementation will restore the depressed Se status among children with burn injuries. The secondary hypothesis is that Se status is related to the incidence of infection among pediatric patients with burns.
Primary Outcome
plasma selenium of all subjects was assessed
Interventions
- DRUG Placebo
- DRUG Selenium1
- DRUG Selenium2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2009-01 |
| Est. Completion | 2019-12 |
| Phase | Phase 4 |
Why NCT00860379 stopped before completion
NCT00860379 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00860379 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00860379 about?
NCT00860379 is a clinical study titled "The Effect of Selenium Supplementation Among Pediatric Patients With Burns". The selenium status of children with major burns is suboptimal which may increase the incidence of infection. Se requirements during critical illness are not known. Results from this investigation may provide a tool for recommending Se supplements during burn injury. The hypothesis of this research...
What is the current status of trial NCT00860379?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2009-01. Estimated completion is 2019-12.
What interventions are being tested in trial NCT00860379?
The interventions under investigation include: Placebo (DRUG), Selenium1 (DRUG), Selenium2 (DRUG).
Who is sponsoring clinical trial NCT00860379?
This trial is sponsored by Shriners Hospitals for Children, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00860379's enrollment target sits among peer trials
14 1901st of 2000 higher than 91 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia